

August 17, 2023

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir/Madam,

Ref: Advisory letter under SEBI (LODR) Regulations, 2015 dated June 14, 2023, received from National Stock Exchange of India Limited.

We received the enclosed advisory letter from National Stock Exchange of India Limited (NSE) advising us to file an update in case of a delay in the timeline for completion of any proposed transaction disclosed to the stock exchanges and to avoid recurrence of such lapses.

As advised by NSE, the above advisory letter was sent to the stock exchanges viz. BSE Limited and NSE on June 15, 2023, and the stock exchanges disseminated the letter on the same day on their websites. Further, the advisory letter was placed before the Board of Directors of the Company at its meeting held on August 12, 2023, and the Board of Directors took note of the same.

The Board and the Company reiterated its commitment to exercising utmost care and caution in achieving compliance with applicable laws including the SEBI (LODR) Regulations, 2015 relating to disclosure of information and will strive to strengthen the same further and advised to provide timely disclosure to the Stock Exchanges in case of any delays in completion of transactions.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LIMITED

www.aurobindo.com

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833
Email: info@aurobindo.com Website: www.aurobindo.com



National Stock Exchange Of India Limited

Ref: NSE/LIST/COMP/ AUROPHARMA/01

Date: June 14, 2023

To,
Aurobindo Pharma Limited
Plot No. 2, Maithrivihar,
Ameerpet, Hyderabad - 500 038,
Telangana.

Sub: Advisory letter under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulations').

Dear Sir/Madam,

This has reference to the disclosure submitted by Aurobindo Pharma Limited ("the Company") on August 18, 2022 w.r.t the completion of acquisition of 51% equity shares in GLS Pharma Limited ("GLS") by the Company.

On June 18, 2022, the Company had intimated the Exchange regarding acquisition of 51% equity shares of GLS wherein the indicative time period for completion of the acquisition was stated to be before July 31, 2022. Further, the Company had intimated the Exchange that the aforesaid acquisition of 51% equity shares of GLS was completed on August 17, 2022 via intimation filed on August 18, 2022.

The Exchange sought clarification from the Company with respect to the reason for delay to provide an update on the extended timeline of acquisition. Company in its reply stated that the delay in completion of the transaction was due to delay in (i) fulfilment of one of the conditions precedent of the acquisition and (ii) credit/transfer of the shares from one of the seller's account to the Company's account.

The Company was required to file an update in case of delay in the timeline for completion of acquisition. It is pertinent to note that when a company files a disclosure informing about an event, all other events in the said matter thereafter would be considered to be material under the provisions of Regulation 30(7) of the Regulations and therefore, disclosure of all such events shall be made to the Stock Exchange under provisions of Regulation 4(1) and 30 of the Regulations.

Considering the aforesaid, the Company is hereby advised to be careful in future to avoid recurrence of such lapses and exercise due diligence while submitting disclosures to the Stock Exchange. You are requested to ensure that the Company files relevant and adequate information regarding material events / incidents impacting the Company in compliance with the Regulations not only in letter but in spirit. Filing incomplete information or delay in disclosing the details as

This Document is Digitally Signed



Signer: DHAVAL SHAH
Date: Wed, Jun 14, 2023 20:00:26 IST
Location: NSE



National Stock Exchange Of India Limited

required under the Regulations in future, would attract suitable disciplinary action, as may be deemed fit.

You are advised to place this letter before the Company's Board of Directors in the upcoming board meeting and disseminate the letter to the Stock Exchanges.

Yours faithfully,
For **National Stock Exchange of India Limited**

Dhaval Shah
Manager

This Document is Digitally Signed

Signer: DHAVAL SHAH
Date: Wed, Jun 14, 2023 20:00:26 IST
Location: NSE



National Stock Exchange of India Limited | Exchange Plaza, C-1, Block G, Bandra Kuria Complex, Bandra (E), Mumbai – 400 051,
India +91 22 26598100 | www.nseindia.com | CIN U67126MH1992PLC0659769